重度の下肢外傷における皮弁のカバレッジの加速 (FLAP ATTACK)
重度の下肢筋骨格損傷の治療における皮弁適用の加速と標準的なタイミングの比較
The goal of this randomized controlled trial is to determine if accelerated flap coverage compared to standard flap coverage timing leads to improved infection-related complications in patients with open fractures and/or dislocations below the knee. Eligible patients will be randomized to receive either a flap within a goal of 72 hours of injury or standard of care flap timing for the institution. The primary outcome will be a composite outcome to evaluate clinical status 6 months after randomization. Components of the composite outcome will be hierarchically assessed in the following order: 1) all-cause mortality, 2) amputation related to injury, 3) re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure), and 4) days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility).
This is the vanguard and international part of the FLAP ATTACK trial.
調査の概要
状態
詳細な説明
Infection following severe lower extremity musculoskeletal injuries is a challenging problem. Several factors hypothesized to influence infection have been explored and, in many cases, optimized or found not to be influential. A persistent area of uncertainty and variability is the timing of acute soft tissue coverage. In the United States, the mean time to coverage from injury is 10 days, and infection rates are 20-35%. In the United Kingdom, there are national guidelines to support coverage within 72 hours of injury, and infection rates are less than 10%. While the data to support early coverage is promising, the necessary evidence to make this significant change is lacking. To justify the mobilization of resources and expense required to shift practice, a definitive trial is needed. This trial seeks to fill this critical knowledge gap.
The primary objective of this trial is to determine if accelerated flap coverage (within 72 hours of injury) compared to standard flap coverage timing leads lower rates of infection and infection-related complications. The trial population includes patients 18 years and older with an acute open fracture and/or dislocation below the knee, with a diagnosed need for acute soft tissue coverage with a flap. Patients who undergo primary amputation prior to attempted flap coverage will be excluded. There will be 356 participants randomized in 1:1 ratio to receive either accelerated flap coverage (goal of flap within 72 hours from injury) or flap coverage at the time that reflects the standard of care at each institution. The timing of the trial interventions, other adjunctive treatments, the fracture fixation, and flap coverage procedures will be documented for both treatment groups. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups. Participants will have follow-up at 6 weeks, 3 months, 6 months, and 12 months post-randomization.
The primary outcome will be a composite outcome to evaluate clinical status 6 months after randomization. Components of the composite outcome will be hierarchically assessed in the following order: 1) all-cause mortality, 2) amputation related to injury, 3) re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure), and 4) days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility). The secondary outcomes will independently assess the individual components of the primary outcome at 6 and 12 months, the composite outcome at 12 months, and health-related quality of life and patient satisfaction over 6 and 12 months. An Adjudication Committee will review primary and secondary endpoints and a Data Safety Monitoring Committee (DSMC) will review all safety events.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Lily Mundy, MD
- 電話番号:410-706-2492
- メール:LMundy3@jhu.edu
研究場所
-
-
California
-
Sacramento、California、アメリカ、95817
- 募集
- UC Davis Medical Center
-
コンタクト:
- Ara A Salibian, MD
-
主任研究者:
- Ara A Salibian, MD
-
主任研究者:
- Augustine M Saiz, MD
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- 募集
- The Johns Hopkins Hospital
-
コンタクト:
- Lily R Mundy, MD
-
主任研究者:
- Lily R Mundy, MD
-
Baltimore、Maryland、アメリカ、21224
- 募集
- John Hopkins Bayview Medical Center
-
コンタクト:
- Lily R Mundy, MD
-
主任研究者:
- Lily R Mundy, MD
-
Baltimore、Maryland、アメリカ、21201
- 募集
- R Adams Cowley Shock Trauma Center
-
コンタクト:
- Mark J Gage, MD
-
主任研究者:
- Mark J Gage, MD
-
Largo、Maryland、アメリカ、20774
- 募集
- University of Maryland Capital Region Medical Center
-
コンタクト:
- Todd Jaeblon, MD
-
主任研究者:
- Todd Jaeblon, MD
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- 募集
- Oregon Health & Science University
-
コンタクト:
- Graham J DeKeyser, MD
-
主任研究者:
- Graham J DeKeyser, MD
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- 募集
- Vanderbilt University Medical Center
-
コンタクト:
- Lauren M Tatman, MD
-
主任研究者:
- Lauren M Tatman, MD
-
-
-
-
Victoria
-
Melbourne、Victoria、オーストラリア、3004
- 募集
- The Alfred Hospital
-
コンタクト:
- Lipi Shukla, MBBS, PhD
-
主任研究者:
- Lipi Shukla, MBBS, PhD
-
-
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V5Z 1N1
- 募集
- Vancouver General Hospital
-
コンタクト:
- David Stockton, MD
- 電話番号:604-875-4111
- メール:david.stockton@vch.ca
-
-
New Brunswick
-
Saint John、New Brunswick、カナダ、E2L 4L2
- 募集
- Saint John Regional Hospital
-
コンタクト:
- Alison Wong, MD
- 電話番号:506-648-6000
- メール:alison.wong@dal.ca
-
-
Ontario
-
Toronto、Ontario、カナダ、M4N 3M5
- 募集
- Sunnybrook Health Sciences Centre
-
コンタクト:
- Jana Dengler
- 電話番号:416-480-6100
- メール:jana.dengler@sunnybrook.ca
-
-
-
-
-
Barcelona、スペイン、08035
- 募集
- Vall d'Hebron University Hospital
-
コンタクト:
- Jordi Tomás-Hernández, MD
-
主任研究者:
- Antonio Bulla, MD, PhD
-
主任研究者:
- Jordi Tomás-Hernández, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
The inclusion criteria are:
- Patients 18 years of age or older.
- Severe lower extremity open fracture and/or dislocation below the knee requiring an acute flap for management of the musculoskeletal injury.
- Will have all planned flap surgeries performed by a participating surgeon or delegate.
- Able to be randomized within 48 hours of injury.
The exclusion criteria are:
- Site is unable to implement the accelerated flap protocol due to local logistics.
- Primary amputation anticipated prior to attempted flap for management of the injury.
- Critical limb ischemia that requires re-vascularization for limb perfusion.
- Chronic or acute infection at or near the musculoskeletal injury site at the time of initial injury surgery.
- Burns at the musculoskeletal injury site.
- Incarceration.
- Expected injury survival of less than 12 months.
- Terminal illness with expected survival of less than 12 months.
- Currently enrolled in a trial that does not permit co-enrollment.
- Declined to provide informed consent.
- Unable to obtain informed consent due to language barriers.
- Unable to obtain informed consent because a legally authorized representative was unavailable.
- Anticipated problems, in the judgment of research personnel, with maintaining follow-up with the patient.
- Prior enrollment in the trial.
- Eligible patient or LAR was not approached within screening window (missed participant).
- Other reason to exclude the patient, as approved by the Principal Investigators.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Accelerated Flap Coverage
Accelerated flap surgery timing at a goal of within 72 hours from injury. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups. |
Timing of the flap surgery is with a goal of 72 hours from injury |
|
アクティブコンパレータ:Standard of Care Flap Timing
The flap surgery will be performed at the standard of care timing for the institution. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups. |
Timing of the flap surgery is the standard of care flap timing for the participating institution. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Clinical status
時間枠:6 months
|
Clinical status is a hierarchical composite of the following outcomes:
|
6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Mortality
時間枠:6 months and 12 months
|
All-cause mortality. Mortality will be time-to-event, with the assumption that earlier is worse than later. |
6 months and 12 months
|
|
Amputation
時間枠:6 months and 12 months
|
Amputation related to injury. Amputation will be time-to-event, with the assumption that earlier is worse than later. |
6 months and 12 months
|
|
Unplanned re-operation
時間枠:6 months and 12 months
|
Unplanned re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure). Re-operation for infection and major flap complication will account for more than one operation, assuming that more operations are worse. |
6 months and 12 months
|
|
Number of days in hospital
時間枠:6 months and 12 months
|
Days in an acute in-patient hospital (i.e., not rehab or nursing facility) |
6 months and 12 months
|
|
Patient-reported health status as assessed by the Euro-QoL (EQ-5D-5L)
時間枠:6 months and 12 months
|
Patient-reported health status as assessed by the EQ-5D-5L. The EQ-5D-5L is scored on a 0 to 100 mm scale. 0 mm represents "the worst health you can imagine to 100 mm which represents "the best health you can imagine". |
6 months and 12 months
|
|
Quality of life as assessed by the Limb-Q
時間枠:6 months and 12 months
|
Health-related quality of life and patient satisfaction measured with the Limb-Q. The Limb-Q is a set of independently functioning scales. All scales are scored 0-100 (higher = better). The Limb-Q Appearance, Physical, Symptoms, Financial Impact, Life Impact, and Psychological scales will be used. |
6 months and 12 months
|
|
Clinical Status
時間枠:12 months
|
Clinical status is a hierarchical composite of the following outcomes: 1. All-cause mortality 2. Amputation related to injury 3. Re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure) 4. Days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility) |
12 months
|
協力者と研究者
スポンサー
協力者
捜査官
- 主任研究者:Lily Mundy, MD、Johns Hopkins School of Medicine
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。